Synonyms: ACE-011 | ACE011 | ActRIIA-IgG1 | MK-7962 | MK7962
Compound class:
Antibody
Comment: Sotatercept (MK-7962) is a soluble activin receptor 2A (ACVR2A; ActR2) ligand trap type inhibitor. Structurally it is a fusion protein of the extracellular domain of the ActR2 and a human IgG Fc domain. In pulmonary blood vessels sotatercept sequesters ActR2 endogenous ligands (e.g. activins A and B, and growth differentiation factors 8 and 11, BMP6 and BMP7), and prevents their interaction with ActR2s to restore normal cell proliferation [2,5].
|
No information available. |
Summary of Clinical Use |
Sotatercept (MK-7962, formerly ACE-011) is in advanced stage clinical development for the treatment of pulmonary arterial hypertension (PAH) [3,6], in which excessive activin pathway signaling is associated with the aberrant pulmonary vascular remodeling and cellular proliferation that characterises PAH. It was granted FDA orphan drug designation for PAH in May 2019. Sotatercept is also being evaluated for the treatment of anaemia, bone loss (in cancer) and myelodysplastic syndromes. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT03496207 | A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH) | Phase 2 Interventional | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | 1 | |
NCT04576988 | A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR) | Phase 3 Interventional | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | 4,7 |